Finance

Lists
4536:TYO
Santen Pharmaceutical Co Ltd
1 734,00 JP¥
+0,73%
(+12,50) 1D
23 հոկ, 15:30:00 GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4536...
Open
1 754 JP¥
High
1 761 JP¥
Low
1 734 JP¥
Mkt. cap
558,89 մլրդ
Avg. vol.
1,28 մլն
Volume
1,14 մլն
Dividend
2,19%
Quarterly dividend
10 JP¥
Ex-dividend date
29 սեպ, 2026 թ.
P/E ratio
14,47
52-wk high
2 254 JP¥
52-wk low
1 458 JP¥
EPS
120 JP¥
Shares outstanding
407,09 մլն
No. of employees
4 հզր
Open
1 754 JP¥
High
1 761 JP¥
Low
1 734 JP¥
Mkt. cap
558,89 մլրդ
Avg. vol.
1,28 մլն
Volume
1,14 մլն
Dividend
2,19%
Quarterly dividend
10 JP¥
Ex-dividend date
29 սեպ, 2026 թ.
P/E ratio
14,47
52-wk high
2 254 JP¥
52-wk low
1 458 JP¥
EPS
120 JP¥
Shares outstanding
407,09 մլն
No. of employees
4 հզր
News stories
From web sources and news partners
Profile
Santen Pharmaceutical Co., Ltd., is a Japanese pharmaceutical company, specializing in ophthalmology. With its ophthalmic products Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide, with its products being sold in over 50 countries. The company was founded in 1890 by Kenkichi Taguchi, as Taguchi Santendo, and in 1925, Santendo Co., Ltd. was established. In 2014 Santen announced that it has entered into an agreement with Merck & Co. to purchase Merck's ophthalmology products. Wikipedia
About Santen Pharmaceutical Co Ltd
CEOAkira Kurokawa | Shigeo Taniuchi
Employees3,97 հզր
Founded1890
HeadquartersՕսակա, Kansai, Ճապոնիա
Sector-
Websitesanten.com
Next call 12 օրից
նոյ 5, հնգ, 09:30
Fiscal period
Q2 2027
- / -
Revenue / Est. (JPY)
- / 72,80 մլրդ
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
69,14 մլրդ
72,88 մլրդ
80,86 մլրդ
68,96 մլրդ
Cost of goods sold
29,06 մլրդ
32,14 մլրդ
29,07 մլրդ
28,97 մլրդ
Cost of revenue
29,06 մլրդ
32,14 մլրդ
29,07 մլրդ
28,97 մլրդ
Research and development expenses
6,16 մլրդ
6,00 մլրդ
7,81 մլրդ
6,25 մլրդ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
21,31 մլրդ
22,27 մլրդ
19,75 մլրդ
23,38 մլրդ
Operating expense
29,74 մլրդ
30,45 մլրդ
33,79 մլրդ
31,87 մլրդ
Total operating expenses
58,80 մլրդ
62,58 մլրդ
62,86 մլրդ
60,84 մլրդ
Operating income
10,34 մլրդ
10,30 մլրդ
18,01 մլրդ
8,12 մլրդ
Other non operating income
-
2,00 մլն
117,00 մլն
-2,00 մլն
EBT including unusual items
10,18 մլրդ
10,44 մլրդ
19,37 մլրդ
8,33 մլրդ
EBT excluding unusual items
10,18 մլրդ
10,44 մլրդ
17,82 մլրդ
8,33 մլրդ
Income tax expense
2,19 մլրդ
2,30 մլրդ
3,80 մլրդ
1,14 մլրդ
Effective tax rate
21,53%
22,00%
19,64%
13,62%
Other operating expenses
-6,00 մլն
-28,00 մլն
-933,00 մլն
-55,00 մլն
Net income
8,06 մլրդ
7,88 մլրդ
15,55 մլրդ
7,19 մլրդ
Net profit margin
11,66%
10,81%
19,23%
10,43%
Earnings per share
-
-
-
-
Interest and investment income
257,00 մլն
455,00 մլն
195,00 մլն
957,00 մլն
Interest expense
-415,00 մլն
-318,00 մլն
-
-738,00 մլն
Net interest expenses
-158,00 մլն
137,00 մլն
195,00 մլն
219,00 մլն
Depreciation and amortization charges
-2,18 մլրդ
-
-6,65 մլրդ
-
EBITDA
15,03 մլրդ
14,92 մլրդ
22,56 մլրդ
12,84 մլրդ
Gain or loss from assets sale
-
-
3,84 մլրդ
-
AI content may include mistakes. Learn more
Google Apps